CAR T therapies drive into new terrain

被引:36
作者
Kingwell, Katie
机构
关键词
D O I
10.1038/nrd.2017.84
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The FDA could soon approve the first chimeric antigen receptor (CAR) T therapies for blood cancers, but this young field is still working on how to address solid tumours, safety concerns and manufacturing issues.
引用
收藏
页码:301 / 304
页数:4
相关论文
共 9 条
[1]  
2016, CANC RES, V76, P1578
[2]  
2011, SCI TRANSL MED, V3
[3]  
2017, CELL, V168, P724
[4]  
2013, MOL THER, V21, P904
[5]  
2017, SCI TRANSL MED, V9
[6]  
2017, NATURE, V543, P113
[7]  
2016, SCI TRANSL MED, V8
[8]  
2013, NAT BIOTECHNOL, V31, P71
[9]  
2014, MOL THER, V22, P1211